These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 15894656)

  • 21. Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from hngh-risk patients.
    Isaacs C; Cavalli LR; Cohen Y; Pennanen M; Shankar LK; Freedman M; Singh B; Liu M; Gallagher A; Rone JD; Dickson RB; Sidransky D; Haddad BR
    Breast Cancer Res Treat; 2004 Mar; 84(2):99-105. PubMed ID: 14999140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Lubinski J; Lynch HT; Klijn J; Ghadirian P; Neuhausen SL; Kim-Sing C; Foulkes WD; Moller P; Isaacs C; Domchek S; Randall S; Offit K; Tung N; Ainsworth P; Gershoni-Baruch R; Eisen A; Daly M; Karlan B; Saal HM; Couch F; Pasini B; Wagner T; Friedman E; Rennert G; Eng C; Weitzel J; Sun P; Narod SA; ; Garber J; Osborne M; Fishman D; McLennan J; McKinnon W; Merajver S; Olsson H; Provencher D; Pasche B; Evans G; Meschino WS; Lemire E; Chudley A; Rayson D; Bellati C
    Breast Cancer Res Treat; 2007 Oct; 105(2):221-8. PubMed ID: 17245541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of cytomorphology in specimens obtained by random periareolar fine needle aspiration and ductal lavage from women at high risk for development of breast cancer.
    Zalles CM; Kimler BF; Simonsen M; Clark JL; Metheny T; Fabian CJ
    Breast Cancer Res Treat; 2006 May; 97(2):191-7. PubMed ID: 16322885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ductal approaches to assessment and management of women at high risk for developing breast cancer.
    Locke I; Mitchell G; Eeles R
    Breast Cancer Res; 2004; 6(2):75-81. PubMed ID: 14979910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of magnetic resonance imaging in screening women at high risk of breast cancer.
    Warner E
    Top Magn Reson Imaging; 2008 Jun; 19(3):163-9. PubMed ID: 18941396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atypia and DNA methylation in nipple duct lavage in relation to predicted breast cancer risk.
    Euhus DM; Bu D; Ashfaq R; Xie XJ; Bian A; Leitch AM; Lewis CM
    Cancer Epidemiol Biomarkers Prev; 2007 Sep; 16(9):1812-21. PubMed ID: 17855699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
    Lee E; Ma H; McKean-Cowdin R; Van Den Berg D; Bernstein L; Henderson BE; Ursin G
    Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3170-8. PubMed ID: 18990759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers.
    Antoniou AC; Shenton A; Maher ER; Watson E; Woodward E; Lalloo F; Easton DF; Evans DG
    Breast Cancer Res; 2006; 8(6):R72. PubMed ID: 17187672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mammary ductoscopy for evaluation of nipple discharge.
    Kapenhas-Valdes E; Feldman SM; Cohen JM; Boolbol SK
    Ann Surg Oncol; 2008 Oct; 15(10):2720-7. PubMed ID: 18685898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytomorphology as a risk predictor: experience with fine needle aspiration biopsy, nipple fluid aspiration, and ductal lavage.
    Masood S
    Clin Lab Med; 2005 Dec; 25(4):827-43, viii-ix. PubMed ID: 16308095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ductal lavage in the screening of high-risk women.
    Kenney PJ; Ellison MC
    Curr Womens Health Rep; 2003 Apr; 3(2):151-5. PubMed ID: 12628085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast cancer screening, outside the population-screening program, of women from breast cancer families without proven BRCA1/BRCA2 mutations: a simulation study.
    Jacobi CE; Nagelkerke NJ; van Houwelingen JH; de Bock GH
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):429-36. PubMed ID: 16537697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Lubinski J; Lynch HT; Neuhausen SL; Ghadirian P; Isaacs C; Weber B; Kim-Sing C; Foulkes WD; Gershoni-Baruch R; Ainsworth P; Friedman E; Daly M; Garber JE; Karlan B; Olopade OI; Tung N; Saal HM; Eisen A; Osborne M; Olsson H; Gilchrist D; Sun P; Narod SA
    Cancer Causes Control; 2005 Aug; 16(6):667-74. PubMed ID: 16049805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study.
    Kotsopoulos J; Librach CL; Lubinski J; Gronwald J; Kim-Sing C; Ghadirian P; Lynch HT; Moller P; Foulkes WD; Randall S; Manoukian S; Pasini B; Tung N; Ainsworth PJ; Cummings S; Sun P; Narod SA;
    Cancer Causes Control; 2008 Dec; 19(10):1111-9. PubMed ID: 18509731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mammographic density does not correlate with Ki-67 expression or cytomorphology in benign breast cells obtained by random periareolar fine needle aspiration from women at high risk for breast cancer.
    Khan QJ; Kimler BF; O'Dea AP; Zalles CM; Sharma P; Fabian CJ
    Breast Cancer Res; 2007; 9(3):R35. PubMed ID: 17537236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breast MR imaging screening in eight women proved or suspected to be carriers of BRCA1&2 gene mutations.
    Cilotti A; Caligo MA; Cipollini G; Francesca D; Marini C; Moretti M; Roncella M; Bartolozzi C; Bevilacqua G
    J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):137-40. PubMed ID: 12585668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
    Simchoni S; Friedman E; Kaufman B; Gershoni-Baruch R; Orr-Urtreger A; Kedar-Barnes I; Shiri-Sverdlov R; Dagan E; Tsabari S; Shohat M; Catane R; King MC; Lahad A; Levy-Lahad E
    Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3770-4. PubMed ID: 16537453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.